This successful trial outcome de-risks CMND-100 development and could attract partnership or licensing interest. Traders should monitor for upcoming trial data readouts and potential Phase IIb initiation, which may catalyze further upside.
Price Chart
Executive Summary
Clearmind Medicine announced that its drug candidate CMND-100 met the primary safety and tolerability endpoint in the Phase I/IIa clinical trial for Alcohol Use Disorder (AUD), supporting advancement to next stages. The trial demonstrated favorable safety even at higher doses, with no serious adverse events reported in the third cohort.
Key Facts
- CMND-100 met primary endpoint (safety and tolerability) in Phase I/IIa trial for AUD
- Drug was well tolerated with no serious adverse events in third cohort
- Trial included dose escalation, supporting higher dosage safety
- CMND-100 is a non-hallucinogenic, MEAI-based oral candidate
- Company is clinical-stage with 31 granted patents and 19 patent families
Financial Impact
Non-dilutive value inflection based on clinical milestone achievement; no immediate revenue but significant optionality increase
Risk Factors
- Next-stage trial funding requirements may lead to dilution
- Future efficacy data could fail to confirm preliminary benefit
- Regulatory path remains uncertain beyond Phase I/IIa
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276876 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $6.12 (−2.02%) |
Oct 13, 2026 13d ago | 6-K | $6.23 | awaiting T+60 | — | $6.12 (−1.75%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $6.12 (−10.82%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $6.12 (+548.41%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $6.12 (+494.27%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $6.12 (−427.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers